2. 筋萎縮性側索硬化症
[臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04516096
(ClinicalTrials.gov)
November 22, 20209/8/2020A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)AMX0035 for Amyotrophic Lateral Sclerosis - Compassionate Use ProtocolAmyotrophic Lateral SclerosisDrug: AMX0035Amylyx Pharmaceuticals Inc.NULLEnrolling by invitation18 YearsN/AAll40Phase 2;Phase 3United States
2NCT03488524
(ClinicalTrials.gov)
March 29, 201823/3/2018Open Label Extension Study of AMX0035 in Patients With ALSOpen Label Extension Study of AMX0035 in Patients With ALSAmyotrophic Lateral Sclerosis;ALSDrug: AMX0035Amylyx Pharmaceuticals Inc.Massachusetts General Hospital Neurology Clinical Research InstituteEnrolling by invitationN/AN/AAll132Phase 2United States
3NCT03127514
(ClinicalTrials.gov)
June 22, 201712/4/2017AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALSAmyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Diseases;Neurodegenerative Diseases;Spinal Cord Diseases;TDP-43 Proteinopathies;Nervous System Diseases;Central Nervous System DiseasesDrug: AMX0035;Other: PlaceboAmylyx Pharmaceuticals Inc.ALS Finding a Cure Foundation;ALS Association;Northeast ALS Consortium;Massachusetts General Hospital Neurology Clinical Research Institute;Leandro P. Rizzuto FoundationCompleted18 Years80 YearsAll137Phase 2;Phase 3United States